EyePoint, Inc. (EYPT)
| Market Cap | 386.23M -52.7% |
| Revenue (ttm) | 2.79M -94.6% |
| Net Income | -306.64M |
| EPS | -3.76 |
| Shares Out | 86.21M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,393,543 |
| Open | 4.590 |
| Previous Close | 4.630 |
| Day's Range | 4.360 - 4.670 |
| 52-Week Range | 3.950 - 19.110 |
| Beta | 1.74 |
| Analysts | Buy |
| Price Target | 27.36 (+510.71%) |
| Earnings Date | Aug 5, 2026 |
About EYPT
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet ... [Read more]
Financial Performance
In 2025, EyePoint's revenue was $31.37 million, a decrease of -27.50% compared to the previous year's $43.27 million. Losses were -$231.96 million, 77.2% more than in 2024.
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for EYPT stock is "Buy." The 12-month stock price target is $27.36, which is an increase of 510.71% from the latest price.
News
EYPT Investors Have Opportunity to Join EyePoint, Inc. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $EYPT--EYPT Investors Have Opportunity to Join EyePoint, Inc. Fraud Investigation with SBS Law.
EyePoint price target lowered to $20 from $43 at Jones
Jones lowered the firm’s price target on EyePoint (EYPT) to $20 from $43 and keeps a Buy rating on the shares. The company is confident the LUGANO stdudy primary miss…
EyePoint downgraded to Neutral from Buy at Chardan
Chardan downgraded EyePoint (EYPT) to Neutral from Buy with a price target of $5, down from $65. he company’s LUGANO study missing its Phase 3 non-inferiority primary endpoint, and Chardan…
EyePoint downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright downgraded EyePoint (EYPT) to Neutral from Buy without a price target after the failed Phase 3 LUGANO trial of Duravyu in wet age-related macular degeneration. If such an…
EyePoint price target lowered to $17 from $35 at Citi
Citi lowered the firm’s price target on EyePoint (EYPT) to $17 from $35 and keeps a Buy rating on the shares. The firm sees greater risk for the LUCIA stud…
EyePoint downgraded to Sector Perform from Outperform at RBC Capital
RBC Capital last night downgraded EyePoint (EYPT) to Sector Perform from Outperform with a price target of $5, down from $37. The LUGANO study missed its primary non-inferiority endpoint, which…
EyePoint downgraded to Sector Perform from Outperform at RBC Capital
RBC Capital downgraded EyePoint (EYPT) to Sector Perform from Outperform with a price target of $5, down from $37.
Clear Street sees less competition for Ocular after EyePoint miss
Clear Street reiterates a Buy rating on Ocular Therapeutix (OCUL) (OCLX) after its competitor EyePoint (EYPT) reported the LUGANO study did not meet its primary endpoint. The trial miss potentially…
Laidlaw trims EyePoint target, still sees high chance of approval
Laidlaw analyst Yale Jen lowered the firm’s price target on EyePoint (EYPT) to $48 from $50 and keeps a Buy rating on the shares. Although the primary endpoint miss in…
Laidlaw trims EyePoint target, still sees high change of approval
Laidlaw analyst Yale Jen lowered the firm’s price target on EyePoint (EYPT) to $48 from $50 and keeps a Buy rating on the shares. Although the primary endpoint miss in…
B. Riley views EyePoint study miss as positive for 4D Molecular
B. Riley analyst Mayank Mamtani reiterates a Buy rating on 4D Molecular (FDMT) with a $37 price target after EyePoint (EYPT) reported its Phase 3 clinical trial for Duravyu for…
EyePoint price target lowered to $8 from $30 at Jefferies
Jefferies lowered the firm’s price target on EyePoint (EYPT) to $8 from $30 and keeps a Buy rating on the shares. The firm views the LUGANO data as mixed. The…
Why Is EyePoint Pharmaceuticals (EYPT) Stock Down 69% Today?
EyePoint Pharmaceuticals stock was down 69.19% on Monday after a clinical trial update failed to impress investors.
EyePoint downgraded to Neutral from Overweight at JPMorgan
JPMorgan downgraded EyePoint (EYPT) to Neutral from Overweight.
EyePoint Stock Craters 71% After Drug Trial Failure. It May Be an Overreaction.
Duravyu, EyePoint's candidate for wet age-related macular degeneration, misses the mark, but muddled trial data may be to blame.
EyePoint downgraded to Neutral from Overweight at Cantor Fitzgerald
Cantor Fitzgerald downgraded EyePoint (EYPT) to Neutral from Overweight without a price target after the company’s first pivotal Phase 3 clinical trial for Duravyu for the treatment of wet age-related...
Morning Movers: EyePoint plummets following LUGANO trial results
Stock futures are mostly higher as investors begin the week with the Nasdaq leading gains on renewed strength in AI and semiconductor stocks. The AI trade is getting another boost…
EyePoint down 69% at $4.52 as Duravyu phase 3 study endpoint was not met
08:42 EDT EyePoint (EYPT) down 69% at $4.52 as Duravyu phase 3 study endpoint was not met
EyePoint Transcript: Study result
The LUGANO phase III trial for DURAVYU in wet AMD showed non-inferiority to aflibercept when excluding nine patients with vision loss unrelated to wet AMD, alongside a 42% reduction in treatment burden and strong safety. Confidence remains high for the upcoming LUCIA trial and future regulatory submission.
EyePoint Press release: Study result
EyePoint issued a press release on August 17, 2026, disclosing material business information to investors.
EyePoint Slides: Study result
EyePoint has posted slides in relation to its latest quarterly earnings report, which was published on August 17, 2026.
EyePoint announces topline results from LUGANO trial
EyePoint (EYPT) announced topline results from LUGANO, the first pivotal Phase 3 clinical trial for Duravyu for the treatment of wet age-related macular degeneration. Duravyu was non-inferior to on-la...
EyePoint's eye drug misses main goal in late-stage trial
EyePoint said on Monday its experimental eye drug failed to meet its main goal in a late-stage trial.
EyePoint Announces Topline Data from LUGANO, the First of Two Pivotal Phase 3 Clinical Trials for DURAVYU™ 2.7mg in Wet AMD
– DURAVYU was non-inferior to on-label aflibercept control (nominal p-value = 0.0096) in an ad hoc analysis excluding a 4% asymmetric cohort (9 of 211 patients) who experienced vision loss (≥ 15 lette...
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WATERTOWN, Mass., Aug. 14, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious...